FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

COVID-19 testing includes molecular (PCR), antigen (rapid), and antibody (serology) tests, each serving different ...

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv 69978, Israel ...

Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, Department of Medical Microbiology and Immunology, Aarhus University, Bartholin Building, ...

The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing the use of CSL ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, or other spine-related symptoms. Lab tests confirmed she had severe anemia; ...